Drug Trial Radar · NCT05974774
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
Last checked: Nov 19, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,600
Planned (sponsor's estimate)
Start
May 23, 2025
Primary completion
May 23, 2035
Study completion Jun 1, 2039
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- Collaborators
- Cancer Trials Ireland; UNICANCER; Spanish Oncology Genito-Urinary Group
- First posted
- Aug 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study addresses the global topic of treatment optimization, i.e. achieving similar benefit while reducing the duration of treatment, hence hoping to decrease the burden of side-effects, improve quality-of life and reduce resource utilization. The primary goal of de-escalation is to investigate whether using an intermittent regime results in a similar OS to continuous treatment.
Conditions
- Prostate Cancer
Interventions
iMABDrug
no treatment until significant PSA increase as per treating physician at which point patient restarts ADT (LHRH agonist or antagonist) + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide). Once PSA \< 0.2 ng/mL, treatment stops again.
cMABDrug
LHRH agonist or antagonist + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide)
Primary outcomes
What the sponsor says the trial is designed to measure.
- overall survivalTime frame: 10 years from randomisation
- proportion of patients who do not restart their hormonal therapy within 1 year of interrupting their MAB therapy (given as part of the induction phase)Time frame: 1 year from stopping the MAB therapy
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
University Hospitals Copenhagen - Rigshospitalet
Copenhagen, Denmark · Recruiting
Centre Francois Baclesse
Caen, France · Recruiting
Institut Daniel Hollard
Grenoble, France · Recruiting
Clinique La Croix Du Sud
Quint-Fonsegrives, France · Recruiting
CHU de Toulouse - Institut Claudius Regaud - IUCT oncopole
Toulouse, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Hospital De La Santa Creu I Sant Pau
Barcelona, Spain · Recruiting
Hospital Universitario San Carlos
Madrid, Spain · Recruiting
Hospital Universitario Puerta De Hierro
Majadahonda, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.